[Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension].
A group of 13 male and 8 female out-patients (mean age: 40.57 years), with primary arterial hypertension, was submitted to two periods of treatment in a cross-over study with spironolactone and potassium canrenoate. Each preparation was given at the dose of 200 mg/day per os for 21 days, with a 10-day interval between treatments. Both preparations proved active on the systolic and diastolic pressure values controlled 7 days. However, potassium canrenoate showed a greater and more rapid effect, particularly on diastolic arterial pressure, as also demonstrated by the statistical analyses. PRA and aldosteronemia increased with both treatments, but this increase resulted significantly lower with potassium canrenoate. The minor stimulating action on the renin-angiotensin-aldosterone mechanism by potassium canrenoate may be the reason for its greater anti-hypertensive effect. Both treatments were perfectly tolerated locally and systemically.
D000284:Administration, Oral; D000328:Adult; D000450:Aldosterone / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002191:Canrenoic Acid / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011245:Pregnadienes / Q000008:administration & dosage*; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000008:administration & dosage*; D013997:Time Factors
D011245:Pregnadienes; D013148:Spironolactone; D000450:Aldosterone; D002191:Canrenoic Acid; D012083:Renin
Studio clinico sull'efficacia del canrenoato di potassio orale e dello spironolattone nell'ipertensione arteriosa essenziale.